JW Lifescience Corporation (KRX:234080)
South Korea · Delayed Price · Currency is KRW 11,030
-110 (-0.99%)
Last updated: Aug 3, 2026, 3:00 PM KST
JW Lifescience Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 252,721 | 257,829 | 222,478 | 206,860 | 188,931 | 169,817 |
Revenue Growth | 7.19% | 15.89% | 7.55% | 9.49% | 11.26% | -7.47% |
Gross Profit Gross Profit Growth | 72,892 | 72,252 | 57,468 | 52,353 | 47,959 | 49,029 |
Operating Income Operating Income Growth | 33,364 | 33,244 | 35,858 | 30,862 | 27,089 | 28,417 |
Net Income Net Income Growth | 29,185 | 28,606 | 43,988 | 28,144 | 14,961 | 12,914 |
Earnings Per Share EPS Growth | 1885.30 | 1847.38 | 2841.00 | 1817.55 | 966.00 | 828.84 |
EPS Growth | -35.06% | -34.97% | 56.31% | 88.15% | 16.55% | -24.14% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 12,202 | 10,489 | 9,622 | 28,348 | 28,873 | 5,078 |
Total Debt Total Debt Growth | 42,251 | 50,573 | 69,238 | 46,313 | 67,195 | 46,488 |
Net Cash (Debt) Net Cash Growth | -30,049 | -40,084 | -59,616 | -17,965 | -38,322 | -41,410 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1941.12 | -2588.63 | -3850.39 | -1160.20 | -2474.87 | -2657.82 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 47,378 | 40,537 | 50,690 | 37,574 | 14,129 | 30,165 |
Capital Expenditures CapEx Growth | -12,767 | -12,554 | -10,307 | -8,153 | -8,079 | -18,976 |
Free Cash Flow Free Cash Flow Growth | 34,611 | 27,983 | 40,383 | 29,421 | 6,049 | 11,189 |
Free Cash Flow Growth | -7.53% | -30.71% | 37.26% | 386.35% | -45.93% | -63.70% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 28.84% | 28.02% | 25.83% | 25.31% | 25.38% | 28.87% |
Operating Margin | 13.20% | 12.89% | 16.12% | 14.92% | 14.34% | 16.73% |
Pretax Margin | 12.67% | 12.31% | 26.53% | 16.30% | 11.00% | 10.77% |
Profit Margin | 11.55% | 11.09% | 19.77% | 13.61% | 7.92% | 7.60% |
FCF Margin | 13.69% | 10.85% | 18.15% | 14.22% | 3.20% | 6.59% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 550.000 | - | - | 500.000 | 500.000 | 500.000 |
Dividend Per Share Growth | 0% | - | - | 0% | 0% | 0% |
Dividend Yield | 5.06% | - | - | 4.24% | 4.67% | 4.26% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.92 | 6.96 | 3.83 | 7.08 | 12.58 | 16.61 |
Forward PE | - | 9.92 | 9.92 | 9.92 | 9.92 | 9.92 |
P/FCF Ratio | 5.00 | 7.11 | 4.17 | 6.77 | 31.10 | 19.17 |
PS Ratio | 0.68 | 0.77 | 0.76 | 0.96 | 1.00 | 1.26 |